icad inc. (NASDAQ:ICAD - Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $2.94 and traded as high as $3.87. icad shares last traded at $3.74, with a volume of 187,312 shares changing hands.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on ICAD shares. BTIG Research cut icad from a "buy" rating to a "neutral" rating in a research report on Wednesday, April 16th. Craig Hallum lowered icad from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 16th. Laidlaw restated a "hold" rating on shares of icad in a research note on Thursday, April 17th. Finally, Wall Street Zen assumed coverage on icad in a report on Tuesday, May 20th. They issued a "sell" rating on the stock.
Get Our Latest Stock Report on ICAD
icad Stock Performance
The stock has a market cap of $102.47 million, a price-to-earnings ratio of -19.63 and a beta of 1.37. The company has a 50-day simple moving average of $3.78 and a two-hundred day simple moving average of $2.95.
icad (NASDAQ:ICAD - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The technology company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.04. The business had revenue of $4.87 million during the quarter, compared to the consensus estimate of $4.54 million. icad had a negative return on equity of 15.03% and a negative net margin of 26.63%.
Institutional Investors Weigh In On icad
Several institutional investors and hedge funds have recently made changes to their positions in ICAD. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of icad in the first quarter worth $40,000. Goldman Sachs Group Inc. bought a new position in icad during the 1st quarter valued at approximately $44,000. PKS Advisory Services LLC bought a new position in icad during the 4th quarter valued at approximately $53,000. Cubist Systematic Strategies LLC purchased a new stake in icad during the 1st quarter valued at $71,000. Finally, Wells Fargo & Company MN boosted its stake in shares of icad by 51.3% in the 4th quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company's stock worth $72,000 after buying an additional 13,402 shares during the last quarter. Institutional investors own 24.61% of the company's stock.
icad Company Profile
(
Get Free Report)
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Further Reading
Before you consider icad, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and icad wasn't on the list.
While icad currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
